Navigation Links
Perrigo Files Registration Statement On Form S-4 In Connection With Proposed Acquisition Of Elan
Date:8/28/2013

therwise.

Elan's principal source of revenue may remain a royalty on sales of Tysabri®, the potential of Tysabri®, which may be severely constrained by increases in the incidence of serious adverse events (including death) associated with Tysabri® (in particular, by increases in the incidence rate for cases of PML), or by competition from existing or new therapies (in particular, oral therapies), and the potential for the successful development and commercialisation of products, whether internally or by acquisition, especially given the separation of the Prothena business which left Elan with no material pre-clinical research programs or capabilities; Elan's ability to maintain sufficient cash, liquid resources, and investments and other assets capable of being monetised to meet its liquidity requirements; the success of Elan's development activities, and R&D activities in which Elan retains an interest, including, in particular, the impact of the announced discontinuation of the development of bapineuzumab intravenous in mild to moderate Alzheimer's disease; failure to comply with anti-kickback, bribery and false claims laws in the United States, Europe and elsewhere; difficulties or delays in manufacturing and supply of Tysabri®; trade buying patterns; the impact of potential biosimilar competition, the trend towards managed care and health care cost containment, including Medicare and Medicaid; legislation and other developments affecting pharmaceutical pricing and reimbursement (including, in particular, the dispute in Italy with respect to Tysabri® sales), both domestically and internationally; failure to comply with Elan's payment obligations under Medicaid and other governmental programs; exposure to product liability (including, in particular, with respect to Tysabri®) and oth
'/>"/>

SOURCE Perrigo Company
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Perrigo Receives FDA Approval And Commences Launch Of Morphine Sulfate 100ml/5% Oral Solution
2. Perrigo Reports Record Fourth Quarter and Fiscal Year Revenue, Earnings and Cash Flow From Operations
3. Perrigo Company to Present at the UBS Global Life Sciences Conference
4. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
5. Coalition to Save Pure Files Proxy Documents With SEC, Urges Pures Board to Set an Annual Meeting Date
6. Genetics Policy Institute (GPI) Files Additional Legal Arguments in Sherley v. Sebelius Stem Cell Case
7. Human Pheromone Sciences Voluntarily Files With SEC for Termination of Registration
8. 3SBio Inc. Files Annual Report on Form 20-F for Fiscal Year 2011
9. Sequenom, Inc. Files Notice Of Appeal Of Preliminary Injunction Denial
10. Ronald L. Chez Files Amended 13D and Letter to the Board
11. China Cord Blood Corporation Files its Annual Report on Form 20-F
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... Research and Markets ... "Spectroscopy Equipment and Accessories - Global Strategic ... This report analyzes the ... in US$ Thousands by the following Product ... NMR-EPR Spectrometers, Near Infrared (NIR) Spectrometers, IR ...
(Date:8/19/2014)... , Aug. 19, 2014 /PRNewswire/ - iCo Therapeutics Inc. ... today reported results of its Oral Amphotericin B ... reservoirs.  The study, conducted by ImmuneCarta®, the immune ... vitro effectiveness of Oral Amp B in ... in individuals despite intensive treatment with antiretroviral therapy. ...
(Date:8/18/2014)... Diagnostics Inc. (TSX-V: SQD), a life sciences company that ... microarray diagnostics, today announced it will hold an investor ... ET.  During the call, Andrew ... SQI,s recent commercialization progress and then introduce Dr. ... to the Board of Directors of SQI and also ...
(Date:8/18/2014)... HIV Infection Drug Market and Pipeline Insight is a ... infection and the number of deaths due to AIDS has ... the globe. It has been estimated that the death rate ... with the rates for children being even much lower. A ... has been the improved access to antiretroviral drugs and therapy ...
Breaking Biology Technology:Global Spectroscopy Equipment and Accessories - Strategic Business Report 2014 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 3SQI Diagnostics Announces Investor Conference Call with Dr. Allan Pronovost 2SQI Diagnostics Announces Investor Conference Call with Dr. Allan Pronovost 3Global HIV Infection Drug Market Overview 2Global HIV Infection Drug Market Overview 3Global HIV Infection Drug Market Overview 4
... patient monitors and sensors, reported a net loss of $245,000 ... $6 million. , ,Sales were down from nearly $6.6 million ... also down, and the firm's net loss came down from ... at about $3.7 million. , ,Criticare (AMEX:CMD) said that several ...
... Now that spring is in gear, women looking for new ... a "shorts and tee shirts" alternative to the traditional conference ... until Sunday, with yoga in the mornings and two full ... of summer camp. ... Your physical surroundings and the things ...
... the Alzheimer's disease drug market in the United ... percent annually for the next five years. , ... Markets for Alzheimer's Disease Medications 2005," include Pfizer, ... Alzheimer's drug market that generated more than $1.3 ...
Cached Biology Technology:Women in technology confab comes to Wisconsin 2Alzheimer's drug market to hit $5.5 billion by 2009, study says 2
(Date:8/19/2014)... the seas during warm phases and became extinct during ... establishes a link between marine crocodilian diversity and the ... than 140 million years. , The research, led ... France and formerly from the University of Bristol, UK ... Today, crocodiles are ,cold-blooded, animals that mainly live in ...
(Date:8/19/2014)... at the University of Liverpool has found how worms ... with the body. , Dr Paolo Paoletti, alongside his ... mathematical model for earthworms and insect larvae which challenges ... get around. , The most widely accepted model is ... that the central brain of these creatures generates rhythmic ...
(Date:8/19/2014)... available in French . ... and RISKS of physical activity in children,Today the Canadian ... promotion of childhood physical activity and published their position ... and Metabolism ( APNM ). This position ... area of risk of physical activity for children and ...
Breaking Biology News(10 mins):Evolution of marine crocodilians constrained by ocean temperatures 2Secrets of how worms wriggle uncovered 2Taking a stand: Balancing the BENEFITS and RISKS of physical activity in children 2Taking a stand: Balancing the BENEFITS and RISKS of physical activity in children 3
... Scientists who have determined how much carbon is stored ... be used to accelerate global discussion about the strategy ... In an era of competing land use demands, the ... are abundant sources of other ecological goods and services ...
... College of Clinical Pharmacology (ACCP) has awarded ... director of Pediatric Clinical Pharmacology at Children,s National ... Dr. van den Anker, a neonatologist by training, ... contributions to pediatric clinical pharmacology," according to the ...
... 8, 2008-- The McClellan Nuclear Radiation Center (MNRC) in ... to detect corrosion and defects in aircraft structure using ... currently helping soil scientists understand the function of plant ... Scientists at the University of California in Davis present ...
Cached Biology News:Scientists point to forests for carbon storage solutions 2Scientists point to forests for carbon storage solutions 3Scientists point to forests for carbon storage solutions 4Scientists point to forests for carbon storage solutions 5US Air Force technology helps scientists understand plant root function 2
...
The Discovery Series PDQuest 2-D analysis software is used for imaging, analyzing, and databasing two-dimensional electrophoretic gels. The 10-user network license entitles ten users to access data f...
Mouse monoclonal antibody raised against a partial recombinant JRKL. NCBI Entrez Gene ID = JRKL...
Mouse monoclonal antibody to ST8SIA2 - ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 2...
Biology Products: